Ocrevusocrelizumab
According to the FDA label: OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults Relapsing-remitting MS, in pediatric patients 10 years of age and older who weigh 25 kg or more.
60,647 adverse event reports submitted to the FDA (2007–2026)
Top Reported Adverse Events
The most frequently reported events in association with Ocrevus in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.
Show these terms with plain-language definitions
Tap any term below for a plain-language definition.
COVID-19 11,553 reports
The illness caused by the SARS-CoV-2 coronavirus.
Full definition in the glossary →Fatigue 6,150 reports
Extreme tiredness or lack of energy that does not improve with rest.
Full definition in the glossary → See all drugs reporting this event →Urinary Tract Infection 3,760 reports
An infection in the bladder, urethra, or kidneys, often called a UTI.
Full definition in the glossary → See all drugs reporting this event →Headache 3,229 reports
Pain in the head or upper neck.
Full definition in the glossary → See all drugs reporting this event →Multiple Sclerosis 2,963 reports
A condition where the immune system affects the protective covering of nerves, which can disrupt movement and other functions. It often appears in reports as a condition being treated.
Full definition in the glossary →Asthenia 2,685 reports
Physical weakness or lack of strength.
Full definition in the glossary →Gait Disturbance 2,681 reports
Difficulty walking normally, such as an unsteady or altered way of walking.
Full definition in the glossary →Multiple Sclerosis Relapse 2,661 reports
A return or worsening of multiple sclerosis symptoms. It often appears in reports as part of the condition being treated.
Full definition in the glossary →Nasopharyngitis 2,549 reports
The medical term for the common cold, an infection of the nose and throat.
Full definition in the glossary →Pain 2,500 reports
A general report of physical discomfort, used when no more specific location is given.
Full definition in the glossary →Fall 2,497 reports
A report that the person fell down. Falls are tracked because they can signal issues like dizziness, weakness, or balance problems.
Full definition in the glossary →Pneumonia 2,418 reports
An infection that inflames the air sacs in the lungs, which can cause cough, fever, and difficulty breathing.
Full definition in the glossary →Off Label Use 2,405 reports
Using a medication for a condition or in a way that the FDA has not officially approved. This is common and often legal, and a report of it does not mean something went wrong. Doctors sometimes prescribe drugs off label based on their judgment.
Full definition in the glossary →Drug Ineffective 2,396 reports
A report that the medication did not work as expected for the person taking it. This is a reporting category, not a sign the drug is defective. It simply means someone felt it was not helping their condition.
Full definition in the glossary →Infusion Related Reaction 2,177 reports
A reaction that happens during or shortly after a medication is given through an IV infusion.
Full definition in the glossary →
Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.
Who Is Reporting
Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.
By Sex
View reporter sex data as a table
| Sex | Reports |
|---|---|
| Female | 38,411 |
| Male | 14,414 |
| Unknown | 363 |
By Age Group
View age group data as a table
| Age group | Reports |
|---|---|
| 0-17 | 169 |
| 18-34 | 5,568 |
| 35-49 | 11,831 |
| 50-64 | 11,255 |
| 65-74 | 2,661 |
| 75+ | 333 |
This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.
Reported Outcomes
Outcomes recorded in FAERS reports that included Ocrevus. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.
View outcome data as a table
| Outcome | Reports |
|---|---|
| Non-Serious | 30,286 |
| Other Serious | 20,416 |
| Hospitalization | 11,045 |
| Death | 1,490 |
| Disability | 843 |
| Life-Threatening | 701 |
Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.
Report Volume Over Time
Number of FAERS reports received per quarter for Ocrevus. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.
View report trend as a table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 10 |
| 2011 | 13 |
| 2012 | 17 |
| 2013 | 7 |
| 2014 | 12 |
| 2015 | 10 |
| 2016 | 30 |
| 2017 | 1,129 |
| 2018 | 4,995 |
| 2019 | 6,274 |
| 2020 | 5,549 |
| 2021 | 7,193 |
| 2022 | 11,404 |
| 2023 | 8,926 |
| 2024 | 9,566 |
| 2025 | 4,546 |
| 2026 (partial) | 963 |
The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.
Medications commonly reported with Ocrevus
In FDA adverse event reports that mention Ocrevus, these medications appeared most often in the same report.
- Baclofen (3,843 reports)
- Acetaminophen (3,152 reports)
- Gabapentin (3,104 reports)
- Dalfampridine (2,793 reports)
- Ergocalciferol (2,646 reports)
This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.
Related Drugs
Other medications with similar adverse event profiles in FDA FAERS reports.
Data Source
This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.
View this data on the FDA website →Data last updated: June 2026